Tolerability of integrase inhibitors in a real-life setting
Integrase inhibitors have shown better tolerability than other drugs in clinical trials, but some post-marketing data have suggested potential differences among them. We compared rates and reasons for discontinuation of raltegravir-, elvitegravir- and dolutegravir-based regimens in a large cohort of...
Uloženo v:
| Vydáno v: | Journal of antimicrobial chemotherapy Ročník 72; číslo 6; s. 1752 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.06.2017
|
| Témata: | |
| ISSN: | 1460-2091, 1460-2091 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Integrase inhibitors have shown better tolerability than other drugs in clinical trials, but some post-marketing data have suggested potential differences among them.
We compared rates and reasons for discontinuation of raltegravir-, elvitegravir- and dolutegravir-based regimens in a large cohort of HIV-infected patients.
Retrospective analysis of a prospectively followed cohort including all antiretroviral-naive and all virologically suppressed antiretroviral-experienced patients prescribed a first regimen containing raltegravir, elvitegravir or dolutegravir with at least one follow-up visit. Major outcomes were early discontinuation (≤1 year) due to any reason and more specifically due to toxicity. Incidence was calculated as number of episodes per 1000 person-years. Risk factors for discontinuation were assessed by multivariate Cox models.
Early discontinuations due to any reason were 271 (raltegravir), 168 (elvitegravir) and 264 (dolutegravir) per 1000 patient-years ( P = 0.0821). Early discontinuations due to toxicity were 76 (raltegravir), 103 (elvitegravir) and 81 (dolutegravir) per 1000 patient-years ( P = 0.6792). Overall, the most common toxicities leading to discontinuation were neuropsychiatric, osteomuscular or digestive. Most frequent neuropsychiatric manifestations reported at discontinuation were insomnia, dizziness, headache and anxiety irrespective of the integrase inhibitor. Among discontinuations due to toxicity, neuropsychiatric effects were more common with dolutegravir than with raltegravir or elvitegravir ( P = 0.0046). Age (HR 1.04, 95% CI 1.02-1.07, P = 0.0007) was the only independent risk factor for early discontinuation due to toxicity.
Discontinuations due to any reason tended to be less common with elvitegravir, but discontinuations due to toxicity did not differ among integrase inhibitors. Neuropsychiatric toxicity leading to drug discontinuation was more frequent with dolutegravir. |
|---|---|
| AbstractList | Integrase inhibitors have shown better tolerability than other drugs in clinical trials, but some post-marketing data have suggested potential differences among them.
We compared rates and reasons for discontinuation of raltegravir-, elvitegravir- and dolutegravir-based regimens in a large cohort of HIV-infected patients.
Retrospective analysis of a prospectively followed cohort including all antiretroviral-naive and all virologically suppressed antiretroviral-experienced patients prescribed a first regimen containing raltegravir, elvitegravir or dolutegravir with at least one follow-up visit. Major outcomes were early discontinuation (≤1 year) due to any reason and more specifically due to toxicity. Incidence was calculated as number of episodes per 1000 person-years. Risk factors for discontinuation were assessed by multivariate Cox models.
Early discontinuations due to any reason were 271 (raltegravir), 168 (elvitegravir) and 264 (dolutegravir) per 1000 patient-years ( P = 0.0821). Early discontinuations due to toxicity were 76 (raltegravir), 103 (elvitegravir) and 81 (dolutegravir) per 1000 patient-years ( P = 0.6792). Overall, the most common toxicities leading to discontinuation were neuropsychiatric, osteomuscular or digestive. Most frequent neuropsychiatric manifestations reported at discontinuation were insomnia, dizziness, headache and anxiety irrespective of the integrase inhibitor. Among discontinuations due to toxicity, neuropsychiatric effects were more common with dolutegravir than with raltegravir or elvitegravir ( P = 0.0046). Age (HR 1.04, 95% CI 1.02-1.07, P = 0.0007) was the only independent risk factor for early discontinuation due to toxicity.
Discontinuations due to any reason tended to be less common with elvitegravir, but discontinuations due to toxicity did not differ among integrase inhibitors. Neuropsychiatric toxicity leading to drug discontinuation was more frequent with dolutegravir. Integrase inhibitors have shown better tolerability than other drugs in clinical trials, but some post-marketing data have suggested potential differences among them.BackgroundIntegrase inhibitors have shown better tolerability than other drugs in clinical trials, but some post-marketing data have suggested potential differences among them.We compared rates and reasons for discontinuation of raltegravir-, elvitegravir- and dolutegravir-based regimens in a large cohort of HIV-infected patients.AimsWe compared rates and reasons for discontinuation of raltegravir-, elvitegravir- and dolutegravir-based regimens in a large cohort of HIV-infected patients.Retrospective analysis of a prospectively followed cohort including all antiretroviral-naive and all virologically suppressed antiretroviral-experienced patients prescribed a first regimen containing raltegravir, elvitegravir or dolutegravir with at least one follow-up visit. Major outcomes were early discontinuation (≤1 year) due to any reason and more specifically due to toxicity. Incidence was calculated as number of episodes per 1000 person-years. Risk factors for discontinuation were assessed by multivariate Cox models.MethodsRetrospective analysis of a prospectively followed cohort including all antiretroviral-naive and all virologically suppressed antiretroviral-experienced patients prescribed a first regimen containing raltegravir, elvitegravir or dolutegravir with at least one follow-up visit. Major outcomes were early discontinuation (≤1 year) due to any reason and more specifically due to toxicity. Incidence was calculated as number of episodes per 1000 person-years. Risk factors for discontinuation were assessed by multivariate Cox models.Early discontinuations due to any reason were 271 (raltegravir), 168 (elvitegravir) and 264 (dolutegravir) per 1000 patient-years ( P = 0.0821). Early discontinuations due to toxicity were 76 (raltegravir), 103 (elvitegravir) and 81 (dolutegravir) per 1000 patient-years ( P = 0.6792). Overall, the most common toxicities leading to discontinuation were neuropsychiatric, osteomuscular or digestive. Most frequent neuropsychiatric manifestations reported at discontinuation were insomnia, dizziness, headache and anxiety irrespective of the integrase inhibitor. Among discontinuations due to toxicity, neuropsychiatric effects were more common with dolutegravir than with raltegravir or elvitegravir ( P = 0.0046). Age (HR 1.04, 95% CI 1.02-1.07, P = 0.0007) was the only independent risk factor for early discontinuation due to toxicity.ResultsEarly discontinuations due to any reason were 271 (raltegravir), 168 (elvitegravir) and 264 (dolutegravir) per 1000 patient-years ( P = 0.0821). Early discontinuations due to toxicity were 76 (raltegravir), 103 (elvitegravir) and 81 (dolutegravir) per 1000 patient-years ( P = 0.6792). Overall, the most common toxicities leading to discontinuation were neuropsychiatric, osteomuscular or digestive. Most frequent neuropsychiatric manifestations reported at discontinuation were insomnia, dizziness, headache and anxiety irrespective of the integrase inhibitor. Among discontinuations due to toxicity, neuropsychiatric effects were more common with dolutegravir than with raltegravir or elvitegravir ( P = 0.0046). Age (HR 1.04, 95% CI 1.02-1.07, P = 0.0007) was the only independent risk factor for early discontinuation due to toxicity.Discontinuations due to any reason tended to be less common with elvitegravir, but discontinuations due to toxicity did not differ among integrase inhibitors. Neuropsychiatric toxicity leading to drug discontinuation was more frequent with dolutegravir.ConclusionsDiscontinuations due to any reason tended to be less common with elvitegravir, but discontinuations due to toxicity did not differ among integrase inhibitors. Neuropsychiatric toxicity leading to drug discontinuation was more frequent with dolutegravir. |
| Author | Tricas, Amparo Martinez-Rebollar, Maria Gonzalez-Cordon, Ana Martinez, Esteban Mallolas, Josep Padilla, Mireia Peñafiel, Judit Gatell, Jose M de Lazzari, Elisa Blanco, Jose L Blanch, Jordi Rodriguez, Ana Rojas, Jhon Marcos, Maria A Lonca, Montserrat Laguno, Montserrat |
| Author_xml | – sequence: 1 givenname: Judit surname: Peñafiel fullname: Peñafiel, Judit organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 2 givenname: Elisa surname: de Lazzari fullname: de Lazzari, Elisa organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 3 givenname: Mireia surname: Padilla fullname: Padilla, Mireia organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 4 givenname: Jhon surname: Rojas fullname: Rojas, Jhon organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 5 givenname: Ana surname: Gonzalez-Cordon fullname: Gonzalez-Cordon, Ana organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 6 givenname: Jose L surname: Blanco fullname: Blanco, Jose L organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 7 givenname: Jordi surname: Blanch fullname: Blanch, Jordi organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 8 givenname: Maria A surname: Marcos fullname: Marcos, Maria A organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 9 givenname: Montserrat surname: Lonca fullname: Lonca, Montserrat organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 10 givenname: Maria surname: Martinez-Rebollar fullname: Martinez-Rebollar, Maria organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 11 givenname: Montserrat surname: Laguno fullname: Laguno, Montserrat organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 12 givenname: Amparo surname: Tricas fullname: Tricas, Amparo organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 13 givenname: Ana surname: Rodriguez fullname: Rodriguez, Ana organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 14 givenname: Josep surname: Mallolas fullname: Mallolas, Josep organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 15 givenname: Jose M surname: Gatell fullname: Gatell, Jose M organization: Hospital Clínic, University of Barcelona, Barcelona, Spain – sequence: 16 givenname: Esteban surname: Martinez fullname: Martinez, Esteban organization: Hospital Clínic, University of Barcelona, Barcelona, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28333231$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj0tLAzEURoNU7EM3_gCZpZuxSe48ElxJqQ8ouKnrIZncqamZmZpkwP57R6zg6juLwwdnTiZd3yEh14zeMSphuVf10nx80RzOyIxlBU05lWzyj6dkHsKeUlrkhbggUy4AgAObkftt79ArbZ2Nx6RvEttF3HkVcKR3q23sfRgxUYlH5VJnG0wCxmi73SU5b5QLeHXaBXl7XG9Xz-nm9ell9bBJaxAypjJvQIMBrSjUHA2AQaCqMKLmTVMKLYEraTKT83w0FGUAmspSQ8akzEu-ILe_vwfffw4YYtXaUKNzqsN-CBUTgmblT92o3pzUQbdoqoO3rfLH6i-YfwMjfVgx |
| CitedBy_id | crossref_primary_10_3390_ph15121533 crossref_primary_10_1007_s11481_019_09886_7 crossref_primary_10_1111_hiv_13377 crossref_primary_10_1007_s13365_019_00780_9 crossref_primary_10_1089_aid_2020_0078 crossref_primary_10_1007_s11481_021_10042_3 crossref_primary_10_1080_14787210_2023_2203914 crossref_primary_10_1007_s40121_024_01083_1 crossref_primary_10_1007_s13365_020_00870_z crossref_primary_10_1080_14656566_2022_2029409 crossref_primary_10_1007_s40261_019_00783_8 crossref_primary_10_1093_cid_ciy505 crossref_primary_10_1093_ofid_ofac345 crossref_primary_10_1177_0956462420983692 crossref_primary_10_1093_jac_dkz217 crossref_primary_10_1093_cid_ciy426 crossref_primary_10_1371_journal_pone_0210476 crossref_primary_10_1007_s40265_020_01379_9 crossref_primary_10_1080_14787210_2020_1733415 crossref_primary_10_1186_s12981_019_0252_0 crossref_primary_10_1080_14740338_2018_1411903 crossref_primary_10_1093_infdis_jiy503 crossref_primary_10_1093_ofid_ofaa482 crossref_primary_10_3389_fphar_2024_1369757 crossref_primary_10_1007_s12035_018_1273_8 crossref_primary_10_1177_09564624211052884 crossref_primary_10_3389_fcimb_2023_1187999 crossref_primary_10_3389_fimmu_2021_639378 crossref_primary_10_3390_metabo12121202 crossref_primary_10_1111_hiv_12710 crossref_primary_10_1177_1060028019896638 crossref_primary_10_1016_j_bmc_2024_117605 crossref_primary_10_1097_QAI_0000000000002075 crossref_primary_10_1080_17425255_2019_1692814 crossref_primary_10_1097_QCO_0000000000000453 crossref_primary_10_2147_HIV_S411948 crossref_primary_10_1093_cid_ciaf191 crossref_primary_10_1097_QAD_0000000000001746 crossref_primary_10_1097_QAI_0000000000002714 crossref_primary_10_1007_s10461_020_02967_2 crossref_primary_10_1002_jppr_1867 crossref_primary_10_1093_jac_dkab200 crossref_primary_10_1097_MD_0000000000016721 crossref_primary_10_1097_MD_0000000000029070 crossref_primary_10_1097_QAD_0000000000002996 crossref_primary_10_1002_jia2_25227 crossref_primary_10_1080_14787210_2020_1729742 crossref_primary_10_1093_jac_dkz572 crossref_primary_10_1007_s40506_019_00203_7 crossref_primary_10_1097_QAD_0000000000002311 crossref_primary_10_1097_QAD_0000000000001781 crossref_primary_10_5582_bst_2017_01194 crossref_primary_10_1590_s1679_4974202100013_esp1 crossref_primary_10_1093_jac_dky508 crossref_primary_10_1016_S2352_3018_19_30077_3 crossref_primary_10_1093_jac_dkz353 crossref_primary_10_1080_14740338_2020_1764531 crossref_primary_10_1097_QAD_0000000000001557 crossref_primary_10_1097_QAD_0000000000002603 crossref_primary_10_1016_j_eclinm_2025_103246 crossref_primary_10_3390_v14010163 crossref_primary_10_1097_QAD_0000000000001675 crossref_primary_10_1007_s40121_022_00734_5 crossref_primary_10_1186_s12879_024_09202_6 crossref_primary_10_1002_hsr2_71047 crossref_primary_10_1007_s11481_019_09899_2 crossref_primary_10_1016_S2352_3018_20_30232_0 crossref_primary_10_1177_0956462417730474 crossref_primary_10_1007_s43440_023_00515_y crossref_primary_10_1111_hiv_13146 crossref_primary_10_1097_QAI_0000000000002250 crossref_primary_10_2147_DDDT_S358976 crossref_primary_10_1111_hiv_13262 crossref_primary_10_1590_0037_8682_588_2020 crossref_primary_10_1097_MD_0000000000033737 crossref_primary_10_1007_s40278_017_39527_z crossref_primary_10_1177_0956462418815292 crossref_primary_10_1007_s10461_021_03272_2 crossref_primary_10_1080_14740338_2021_1931115 crossref_primary_10_1007_s15010_020_01469_6 crossref_primary_10_1177_23259582221088202 crossref_primary_10_1080_14622416_2024_2441104 crossref_primary_10_1016_j_compbiolchem_2020_107319 crossref_primary_10_1111_hiv_13215 crossref_primary_10_1111_hiv_12688 |
| ContentType | Journal Article |
| Copyright | The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/jac/dkx053 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1460-2091 |
| ExternalDocumentID | 28333231 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 0R~ 18M 1TH 29J 2WC 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAJQQ AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWTL ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACCCW ACGFO ACGFS ACIWK ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECGQY ECM EE~ EIF EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HH5 HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M49 MHKGH ML0 N9A NGC NOMLY NOYVH NPM NU- NVLIB O9- OAUYM OAWHX OBS OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 RHF ROL ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TMA TR2 UCJ W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 7X8 ABPQP ADNBA AEMQT AJBYB AJNCP ALXQX |
| ID | FETCH-LOGICAL-c389t-95f3b3d3ba03c2ed33de30a6d8c2ff78b932a9d4d52503ca0133b097b34199572 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 96 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000404899800027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2091 |
| IngestDate | Thu Oct 02 10:52:11 EDT 2025 Wed Feb 19 02:44:44 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c389t-95f3b3d3ba03c2ed33de30a6d8c2ff78b932a9d4d52503ca0133b097b34199572 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://academic.oup.com/jac/article-pdf/72/6/1752/17234915/dkx053.pdf |
| PMID | 28333231 |
| PQID | 1880470006 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1880470006 pubmed_primary_28333231 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-06-01 |
| PublicationDateYYYYMMDD | 2017-06-01 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of antimicrobial chemotherapy |
| PublicationTitleAlternate | J Antimicrob Chemother |
| PublicationYear | 2017 |
| SSID | ssj0006568 |
| Score | 2.5237684 |
| Snippet | Integrase inhibitors have shown better tolerability than other drugs in clinical trials, but some post-marketing data have suggested potential differences... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1752 |
| SubjectTerms | Adult Cohort Studies Female Heterocyclic Compounds, 3-Ring - adverse effects Heterocyclic Compounds, 3-Ring - therapeutic use HIV Infections - drug therapy HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - adverse effects HIV Integrase Inhibitors - therapeutic use HIV-1 - drug effects Humans Life Style Male Medication Adherence Middle Aged Proportional Hazards Models Quinolones - adverse effects Quinolones - therapeutic use Quinolones - toxicity Raltegravir Potassium - adverse effects Raltegravir Potassium - therapeutic use Retrospective Studies |
| Title | Tolerability of integrase inhibitors in a real-life setting |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28333231 https://www.proquest.com/docview/1880470006 |
| Volume | 72 |
| WOSCitedRecordID | wos000404899800027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3PS8MwFMeDOhEv_pi_5i8iyE4La5u2afAgIg4PbvQwYbeR5gdWRzvtFPff-9J29CQIXkqgBEr6knzy3sv3IXQNzCGES11i4LBMfF8xkrihIknATMg9paUpLwo_sdEomkx4XDvcijqtcrUmlgu1yqX1kfetbpjP7Op6O38ntmqUja7WJTTWUYsCytiJySaNWnhYX4XzQwesgbsreVJO-69C9tXbt2OLIv-GluUWM9j978ftoZ0aLvFdZQ37aE1nbbQ1rMPnbdSNK6HqZQ-Pm3tXRQ93cdxIWC8P0M04n8H7MnF2iXODa1WJQkPrJU1SW6MHmlhggM4ZmaVG40KXOdSH6HnwML5_JHWZBSKBVhaEB4YmVNFEOFR6WlGqNHVEqCLpGcOiBBBPcOUrGwGlUgA00sThLLFScDxg3hHayPJMnyDMqAwc5fo2mAOcRiOPR56CMxIPIsuGHXS1Gr8pmLGNTYhM55_FtBnBDjqufsJ0XultTIGAKAUOPf1D7zO07dmNt_STnKOWgUmsL9Cm_FqkxcdlaR_wHMXDHxS9w-8 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tolerability+of+integrase+inhibitors+in+a+real-life+setting&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=Pe%C3%B1afiel%2C+Judit&rft.au=de+Lazzari%2C+Elisa&rft.au=Padilla%2C+Mireia&rft.au=Rojas%2C+Jhon&rft.date=2017-06-01&rft.issn=1460-2091&rft.eissn=1460-2091&rft.volume=72&rft.issue=6&rft.spage=1752&rft_id=info:doi/10.1093%2Fjac%2Fdkx053&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2091&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2091&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2091&client=summon |